Transcutaneous immunization with Intercell's vaccine delivery system (Q38017392)

27 August 2017

Transcutaneous immunization with Intercell's vaccine delivery system (English)

1 reference

27 August 2017

Robert C Seid

1

1 reference

27 August 2017

Jee Loon Look

2

1 reference

27 August 2017

Christian Ruiz

3

1 reference

27 August 2017

Vladimir Frolov

4

1 reference

27 August 2017

David Flyer

5

1 reference

27 August 2017

Jason Schafer

6

1 reference

27 August 2017

Larry Ellingsworth

7

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

27 August 2017

1 reference

27 August 2017

30

1 reference

27 August 2017

29

1 reference

27 August 2017

4349-4354

1 reference

Transcutaneous immunization: a human vaccine delivery strategy using a patch

27 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Advances in transcutaneous vaccine delivery: do all ways lead to Rome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Harnessing human dendritic cell subsets for medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Insights into Langerhans cell function from Langerhans cell ablation models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Standardized tape stripping prior to patch testing induces upregulation of Hsp90, Hsp70, IL-33, TNF-α and IL-8/CXCL8 mRNA: new insights into the involvement of 'alarmins'

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Topical resiquimod promotes priming of CTL to parenteral antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

The control of protein stability and association by weak interactions with water: how do solvents affect these processes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Rational design of stable lyophilized protein formulations: theory and practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Cytotoxic effects of anthrax lethal toxin on macrophage-like cell line J774A.1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.113

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.09.113

1 reference

27 August 2017

1 reference